Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experienceNeha Papneja, Petr Kavan, Abhishek Papneja et al.|Annals of Oncology|2019Cited by 1
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.Ivan Barrera, Petr Kavan, Neha Papneja et al.|Journal of Clinical Oncology|2020Cited by 0